A randomized controlled clinical study demonstrated that RESPeRATE can significantly relieve symptoms of heart failure in elderly patients. After 4 weeks of twice daily treatment sessions, patients showed a reduction in the severity of CHF measured by NYHA classification and dyspnea.
A study using RESPeRATE, a device-guided paced breathing system, found significant reductions in blood pressure and peripheral resistance in hypertensive patients. The treatment group showed a greater systolic BP reduction correlated with the total time spent in slow breathing.
A randomized controlled study showed a significant reduction in systolic blood pressure (SBP) of 7.4 mmHg in the treatment group, compared to a rise of 3.1 mmHg in the control group. The device also demonstrated a dose-response relationship, with increased breathing exercise sessions resulting in greater SBP reduction.
A new analysis found that a non-drug device-guided slow breathing treatment reduced the white-coat effect by ~80% in patients, compared to ~40% for controls. The treatment was also effective across different patient groups, including pre-hypertensives and resistant hypertensive patients.
A multi-center randomized controlled study found that 45 minutes of weekly self-treatment with RESPeRATE significantly reduces systolic blood pressure, with greater reductions in medicated and non-medicated patients. The device's effectiveness was correlated with slow breathing time, making it easy to use at home.
A new study published in the American Journal of Hypertension demonstrates that 15 minutes of daily RESPeRATE treatment significantly reduces home blood pressure in both medicated and non-medicated patients. The study also shows high patient compliance, with many patients continuing treatment after the trial ended.
Two studies presented at the Heart Failure Society of America annual conference show that an experimental respiratory-pacing device, inTone TM, significantly improves heart failure patients' ejection fraction, pulmonary artery pressure, and quality of life. The device's non-invasive therapy is delivered through a 15-minute session twic...
A new study published in American Journal of Hypertension found that the Resperate device significantly reduced blood pressure in patients with hard-to-control refractory hypertension. The 8-week study demonstrated that daily self-treatment with the device reduced blood pressure, even in those taking multiple antihypertensive medications.
The RESPeRATE TM device is gaining acceptance for its non-drug treatment of hypertension, with a new chapter in the American Heart Association's textbook supporting its therapeutic effect. The device works by reducing sympathetic outflow and peripheral resistance, leading to blood pressure reductions.